Tessera Sector
Top Healthcare Stocks
Pharmaceuticals, biotech, medical devices, and healthcare services. Defensive cash flows often coexist with binary clinical-trial outcomes.
The Healthcare sector registers a mean Tessera Quality Score of 71 against a universe average of 48, placing it meaningfully above the broader cross-sector baseline. That gap suggests the 250 qualifying members cleared relatively demanding quality filters, though individual scores among the top-ranked names still cluster in a modest range, with the highest-scoring holding, VTVT, reaching only 0.63 out of a normalized 1.0.
Valuation context adds nuance to the picture. The sector's median P/E of 25.5 sits at a level that implies the market is pricing in meaningful growth expectations across the cohort. For early-stage or pipeline-dependent names like NRXP and ABUS, earnings-based multiples can be less informative than quality metrics, making the Tessera scoring framework particularly relevant for filtering within this segment of Healthcare. ABUS, with a score of 0.59, represents the midpoint of the top five, reflecting a profile that passes quality thresholds without standing out sharply from its immediate peers.
The concentration of top scores in a relatively tight band — from 0.54 for ROIV to 0.63 for VTVT — points to competitive differentiation at the margin rather than a clear tier separation among leaders. Taken together, Healthcare's sector-level score of 71 positions it as one of the stronger-quality segments relative to the 48-point universe median, indicating that the sector's constituents, on aggregate, exhibit above-average characteristics across whatever quality dimensions the Tessera model weights.
| Ticker | Company | Industry | Score | Mkt Cap | P/E |
|---|---|---|---|---|---|
| VTVT | vTv Therapeutics Inc. | Biotechnology | 82 | $86M | — |
| NRXP | NRx Pharmaceuticals, Inc. | Biotechnology | 81 | $77M | — |
| ABUS | Arbutus Biopharma Corp | Biotechnology | 79 | $893M | 5.5 |
| ELOX | Eloxx Pharmaceuticals, Inc. | Biotechnology | 78 | $91M | — |
| ROIV | Roivant Sciences Ltd. | Biotechnology | 77 | $25.1B | — |
| OSCR | Oscar Health, Inc. | Medical - Healthcare Plans | 77 | $8.0B | — |
| ORMP | Oramed Pharmaceuticals Inc. | Biotechnology | 76 | $165M | 1.6 |
| PLX | Protalix BioTherapeutics, Inc. | Biotechnology | 74 | $190M | 12.9 |
| ZVRA | Zevra Therapeutics, Inc. | Biotechnology | 74 | $736M | 5.8 |
| INDV | Indivior Pharmaceuticals Inc | Drug Manufacturers - Specialty & Generic | 74 | $5.0B | 20.4 |
| INVA | Innoviva, Inc. | Biotechnology | 72 | $1.6B | 3.6 |
| LLY | Eli Lilly and Company | Drug Manufacturers - General | 70 | $1.11T | 41.7 |
| TGTX | TG Therapeutics, Inc. | Biotechnology | 70 | $8.3B | 18.9 |
| ARGX | argenx SE | Biotechnology | 70 | $54.4B | 35.3 |
| LQDA | Liquidia Corporation | Medical - Pharmaceuticals | 69 | $7.2B | 581.5 |
| HNGE | Hinge Health, Inc. | Medical - Healthcare Information Services | 69 | $6.5B | — |
| AMN | AMN Healthcare Services, Inc. | Medical - Care Facilities | 69 | $1.3B | — |
| OKYO | OKYO Pharma Limited | Biotechnology | 69 | $55M | — |
| NUTX | Nutex Health, Inc. | Medical - Care Facilities | 68 | $1.0B | 13.1 |
| ACHV | Achieve Life Sciences, Inc. | Biotechnology | 68 | $667M | — |
| CRMD | CorMedix Inc. | Biotechnology | 67 | $643M | 3.9 |
| AUPH | Aurinia Pharmaceuticals Inc. | Biotechnology | 67 | $2.0B | 7.2 |
| TENX | Tenax Therapeutics, Inc. | Biotechnology | 67 | $270M | — |
| ELMD | Electromed, Inc. | Medical - Devices | 67 | $336M | 34.6 |
| OKUR | OnKure Therapeutics, Inc. | Biotechnology | 67 | $57M | — |
| AVAH | Aveanna Healthcare Holdings Inc. | Medical - Care Facilities | 67 | $2.1B | 8.0 |
| EXEL | Exelixis, Inc. | Biotechnology | 67 | $14.1B | 18.6 |
| KNSA | Kiniksa Pharmaceuticals International, plc | Medical - Pharmaceuticals | 67 | $4.8B | 69.8 |
| KRYS | Krystal Biotech, Inc. | Biotechnology | 67 | $10.0B | 45.3 |
| CPRX | Catalyst Pharmaceuticals, Inc. | Biotechnology | 66 | $3.9B | 18.2 |